Teva commences commercial launch of Escitalopram Oxalate Tablets

Published on March 15, 2012 at 12:42 AM · No Comments

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has commenced commercial launch of Escitalopram Oxalate Tablets, the Company's generic version of Forest Laboratories' depression and generalized anxiety disorder treatment, Lexapro® Tablets. The brand product had annual sales of approximately $2.9 billion in the United States, based on IMS sales data.

As the first company to file an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.

Source: Teva

c2b81b0b-4617-421c-ab3c-b5aadc918126|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Anxiety, Anxiety Disorder, Biotechnology, Depression, Generic Drug, Lexapro, Medicaid, Medicare, New Drug Application, Oncology, Pain, Protonix

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Post a new comment

(Logout)

Quirky Comment Title (optional)

Post

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.